Sign in

    Qu Xiaoyi

    Vice President and Equity Research Analyst at CICC

    Qu Xiaoyi is a Vice President and Equity Research Analyst at CICC, specializing in the semiconductor and technology hardware sectors. She covers leading companies such as Semiconductor Manufacturing International Corporation, Hua Hong Semiconductor, and Will Semiconductor, and has gained recognition for her detailed analysis and actionable investment insights. Since joining CICC in 2019, Qu Xiaoyi has built a reputation for research quality, though specific published performance metrics or formal analyst rankings are not publicly available. She began her finance career after earning advanced degrees in engineering and finance, and is known for her technical expertise and industry knowledge, though there is no public record of FINRA registration or U.S. securities licenses as of this writing.

    Qu Xiaoyi's questions to I-Mab (IMAB) leadership

    Qu Xiaoyi's questions to I-Mab (IMAB) leadership • H1 2023

    Question

    Qu Xiaoyi asked about the expected real-world prevalence of the patient population with high CD73 and PD-L1 expression for uliledlimab, and whether adding chemotherapy could improve response in patients with low PD-L1 expression.

    Answer

    CMO John Hayslip noted that since the trial enrolled patients regardless of CD73 status, the observed rates may be consistent with the real-world population. He and CEO Raj Kannan expressed optimism that combining uliledlimab with chemotherapy could broaden its benefit to more patients, potentially irrespective of their baseline CD73 or PD-L1 expression levels.

    Ask Fintool Equity Research AI